Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Ewa Kozela, Ana Juknat, and Zvi Vogel International Journal of Molecular Sciences, 2017, 18, 1669, 20 pp. doi:10.3390/ijms18081669 PMID : 28788104 PMCID : PMC5578059 Abstract The astrocytes have gained in recent decades an enormous interest as a potential target for neurotherapies, due to their essential and pleiotropic roles in brain physiology and pathology. Their precise regulation is still far from understood, although several candidate molecules/systems arise as promising targets for astrocyte-mediated neuroregulation and/or neuroprotection. The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes. Cannabidiol (CBD) is the main [...]
Lire la suiteCannabinoïd-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patricia Schonhofen, Ivi Juliana Bristot, Jose Alexandre Crippa et al. CNS Drugs, 2018, 32(Suppl 1), 1-16 DOI : 10.1007/s40263-018-0550-4 Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural differentiation, migration and survival. This may potentially confer increased vulnerability to [...]
Lire la suiteCannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications. A new frontier brings new questions and old dilemmas. Adrian L. Turner and M. Scott Perry Practical Neurology, October 2018, 31-35 Background As early as 12,000 BCE, texts from central Asia reported human use of cannabis for nonmedical indications including ropes, fibers, and cloth. Ancient Chinese manuscripts from approximately 10,000 years later give the first documented use of cannabis for medical purposes 1. Other early reports from ancient Mesopotamia, Persia, and India describe cannabis use for indications such as spasticity, depression, anxiety, and epilepsy.1,2 Cannabis for medicinal purposes was not scientifically studied until the 19th century. In 1840, [...]
Lire la suiteNeuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals : a Systematic Review A. Batalla, J.A. Crippa, G.F. Busatto, F.S. Guimarães, A.W. Zuardi, O. Valverde, Z. Atakan, P.K. McGuire, S. Bhattacharyya and R. Martín-Santos Current Pharmaceutical Design, 2014, 20, 2168-2185 DOI : 10.2174/13816128113199990432 Available from: https://www.researchgate.net/publication/247154314_Neuroimaging_Studies_of_Acute_Effects_of_THC_and_CBD_in_Humans_and_Animals_a_Systematic_Review [accessed May 19, 2019]. Abstract : Background : In recent years, growing concerns about the effects of cannabis use on mental health have renewed interest in cannabis research. In particular, there has been a marked increase in the number of neuroimaging studies of the effects of cannabinoids. We conducted a systematic review to assess the [...]
Lire la suiteInvestigational Cannabinoids in Seizure Disorders, what have we learned thus far ? Dejana Ružić Zečević, Ziyad Tantoush, Marko Folić, Goran Babić, Milan Radovanović and Slobodan M. Janković may 2018, 23 pages ABSTRACT Introduction : Anticonvulsant activity of cannabinoid attracted much attention in the last decade. Cannabinoids that are currently investigated with intention to become drugs for treatment of epilepsy are cannabidiol, cannabidivarin, Δ9-tetrahydrocannabivarin and Δ9-tetrahydrocannabinolic acid. Areas covered : Topic of this review are results of pre-clinical and clinical studies with investigational cannabinoids. Relevant literature was searched for in MEDLINE, SCOPUS, EBSCO, GOOGLE SCHOLAR and SCINDEX databases. Expert opinion : Pre-clinical studies confirmed anticonvulsant activity of [...]
Lire la suiteA Phase I, Randomized, Double‑Blind, Placebo‑Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects Lesley Taylor,·Barry Gidal,·Graham Blakey, Bola Tayo, Gilmour Morrison CNS Drugs, 2018 https://doi.org/10.1007/s40263-018-0578-5 Abstract Background : A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters. Objective : This trial assessed the safety, tolerability and PK of CBD oral solution in healthy adult volunteers, as well as the effect [...]
Lire la suiteCannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review Jasmine Turna, Sabrina K. Syan, Benicio N. Frey, Brian Rush, Mary Jean Costello, Mark Weiss, and James MacKillop ALCOHOLISM: CLINICAL AND EXPERIMENTAL RESEARCH, 2019, 1-14 Abstract : There is substantial interest in the therapeutic potential of cannabidiol (CBD), a nonpsychoactive cannabinoid found in plants of the genus Cannabis. The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a candidate pharmacotherapy for alcohol use disorder (AUD). Using a comprehensive search strategy, 303 unique potential articles were identified [...]
Lire la suiteSafety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia : An-Open Label, Add-On, Pilot Study Shelef A., Barak Y., Berger U., Paleacu D., Tadger S., Plopsky I., Baruch Y. Journal of Alzheimer's Disease, 2016, 51, 1, 15-19. DOI: 10.3233/JAD-150915 BACKGROUND : Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). OBJECTIVE : To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD). METHODS : Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. RESULTS : Ten patients completed the trial. Significant reduction [...]
Lire la suiteUsing CBD to Tame a Cannabis High? Small Doses May Have the Opposite Effect Bailey Rahn, February 28, 2019, https://www.leafly.com Posted By Bailey Rahn On February 28, 2019 @ 3:52 pm In Science & Tech https://www.leafly.com/news/science-tech/how-cbd-dose-affects-cannabis-effects/print/ (imaginima/iStock) Take some CBD, they said. You’ll feel less high, they said. This common piece of advice fed to THC-shy consumers can effectively bring someone back down to earth. It works—sometimes. But new research shows there’s likely more nuance in the solution than we initially thought. Scientists found that a high dose of CBD dampened the effects of a THC high, but participants reported a stronger high when combined with low [...]
Lire la suiteLeafly : CBD in the Spotlight at SXSW, Despite Legal Gray Area Written by Tonyia Cone on March 26, 2019. Posted in MAPS in the Media Summary: A new article from Leafly reflects on the Cannabusiness session at South by South West (SXSW) 2019, where MAPS Policy and Advocacy Director Natalie Lyla Ginsberg, M.S.W., represented MAPS through participating in a panel discussion, The Future of Hemp and Health. Originally appearing here. A simple stroll across the festival grounds brought visitors past an array of CBD-focused booths: Kentucky-based MedTerra, for example, hosted a two-day, CBD-focused venue, dubbed “Wellhaus,” that featured a CBD infusion bar. [...]
Lire la suite